Quibim has announced the launch of QP-Liver, an AI-powered diagnostic tool which is designed to improve the diagnosis of diffuse liver diseases.
The tool, which accurately quantifies tissue fat and iron levels from MRI [magnetic resonance imaging] scans, has received clearance in the European Union and the UK, bearing both CE and UKCA marks.
QP-Liver provides automated liver segmentation and can correlate fat and iron quantification using reference digital pathology data.
This innovation is expected to enhance early detection, precise monitoring, and the development of tailored treatment plans for liver disease, while also reducing the reliance on invasive biopsies.
The platform comprises a post-processing solution that utilises multi-echo chemical shift sequences in abdominal MRI examinations to detect and quantify fat content.
It produces parametric maps of fat and iron at a voxel-wise resolution, enabling the generation of structured quantitative reports that compare liver values with normative data.
Quibim co-founder and CEO Angel Alberich-Bayarri said: “QP-Liver represents a significant leap forward in liver imaging analysis. By automating liver segmentation and simultaneously quantifying tissue fat and iron instead of independently, it allows for the highest accuracy and empowers clinicians to make more informed diagnoses for patients with diffuse liver diseases.
“We believe the tool’s impact on liver disease diagnosis is truly remarkable, and it exemplifies the intersection of cutting-edge AI, quantitative algorithms and healthcare.”
Quibim’s tool offers a more comprehensive evaluation of steatosis and iron overload. It corrects biases present in traditional methods, leading to more accurate disease severity assessments and enhancing the quality of radiologist reports.
Last year, Quilbim partnered with Phillips to provide an AI-based imaging and reporting solutions for MR [magnetic resonance] prostate examinations.
